CLSPCOL rescues Alzheimer's disease mouse models

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Calmodulin-like skin protein (CLSP) activity is reduced in Alzheimer's disease (AD), contributing to neurotoxicity.
• CLSP's protective role against AD-related neurotoxicity is established, but its therapeutic potential in early disease stages requires investigation.

Purpose of the Study:

• To evaluate the efficacy of the novel hybrid peptide CLSPCOL in ameliorating early-phase memory deficits in an AD mouse model.
• To assess CLSPCOL's ability to counteract memory impairment induced by cholinergic system disruption, mimicking aspects of AD.
• To determine if CLSPCOL can serve as both a disease-modifying and symptomatic treatment for AD.

Main Methods:

• Development of CLSPCOL, a hybrid peptide combining CLSP(1-61) and adiponectin's collagen-homologous region (COL).
• Administration of CLSPCOL to *APPswe/PS1dE9* double transgenic mice (APP/PS1 mice) at an early disease phase.
• Assessment of memory acquisition using fear-conditioning tests in early-phase AD models.
• Evaluation of CLSPCOL's effect on short-term working memory impairment induced by scopolamine injection.

Main Results:

• CLSPCOL treatment corrected impaired fear-conditioned memory acquisition in an early-phase AD mouse model.
• A single subcutaneous injection of CLSPCOL successfully rescued short-term working memory deficits caused by scopolamine.
• These findings demonstrate CLSPCOL's effectiveness in both early-stage AD pathology and mimicking cholinergic dysfunction.

Conclusions:

• CLSPCOL is a promising therapeutic agent for Alzheimer's disease, effective in both early and advanced stages.
• CLSPCOL demonstrates disease-modifying potential by restoring CLSP activity and symptomatic benefits by enhancing cholinergic neurotransmission.